

Subject: FW: [BULK] Pfizer IGLC Announces Two Educational Grant Offerings on the Use of Biosimilars
Date: Thursday, 16 March 2017 at 08:00:08 Central European Standard Time
From: Jennie De Greef
To: Isabel Valero Guerrero

Please add to the SC agenda with the information below linked. Under Synergy.

From: "Latymer, Mark" <Mark.Latymer@pfizer.com>
Date: Wednesday, 15 March 2017 at 20:25
To: Jennie De Greef <Jennie.DeGreef@eahp.eu>
Subject: FW: [BULK] Pfizer IGLC Announces Two Educational Grant Offerings on the Use of Biosimilars

Dear Jennie,

Hopefully this may be of interest to the EAHP or some of your members.

Pfizer have just released our 2017 European **Call for educational Grant Applications** (see #2 below).

I thought I'd take the opportunity to highlight this. Although long established in the USA this method of providing educational grants is relatively new in Europe.

Warmest regards
Mark

From: Solis, Amanda
Sent: 15 March 2017 19:09
To: Latymer, Mark
Cc: Harbron, Jo
Subject: FW: [BULK] Pfizer IGLC Announces Two Educational Grant Offerings on the Use of Biosimilars

Hi Mark –

This is live and available on our website!

Thanks,
Amanda

From: IGLC
Sent: Wednesday, March 15, 2017 1:49 PM
To: Solis, Amanda
Subject: [BULK] Pfizer IGLC Announces Two Educational Grant Offerings on the Use of Biosimilars





Independent Grants for Learning & Change

Call for Grant Applications (CGA) #1 *Addressing Knowledge Gaps in the Science of Biosimilars for the Specialist in the US*

Date CGA Issued: March 15, 2017

Clinical Area: Biosimilars

Link to full CGA: [Addressing Knowledge Gaps in the Science of Biosimilars](#)

Due Date: April 21, 2017

Geographic Scope: US only

Specific Area of Interest: Education leading to a clear understanding of the appropriate use of biosimilars and other emerging concerns is critical for specialists; including fellows, nurse practitioners, physician assistants, and all other healthcare professionals involved in preparing for their appropriate use in clinical practice.

The intent of this CGA is to support educational programs that seek to improve knowledge and competence of specialists and their respective teams with the science of biosimilars related to their specific practice environment. Proposals should address one or more of the areas of learning needs identified in the full CGA document.

Questions regarding this CGA should be directed to amanda.solis@pfizer.com.

Call for Grant Applications (CGA) #2 *Addressing Knowledge Gaps in the use of Curative Oncology*

Biosimilars in Europe

Date CGA Issued: March 15, 2017

Clinical Area: Biosimilars

Link to full CGA: [Addressing Knowledge Gaps in the Use of Curative Oncology Biosimilars](#)

Due Date: May 11, 2017

Geographic Scope: International: Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and United Kingdom.

Specific Area of Interest: Education leading to a clear understanding of the appropriate use of biosimilars and other emerging concerns is critical for European pharmacists and physicians in preparing for their appropriate use in clinical practice.

The intent of this CGA is to support educational programs that seek to improve both pharmacist and clinician knowledge and competence in the use of curative oncology biosimilars in the European countries listed in the “Geographic Scope” section of this document. Proposals should address one or more of the areas of learning needs identified in the full CGA document.

Questions regarding this CGA should be directed to amanda.solis@pfizer.com.

The mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner

with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

When a CGA is issued, it is posted on the [Pfizer IGLC website](#) and is sent via e-mail to

all registered users in our grants system. Some CGAs may also be posted on the websites of other relevant organizations, as deemed appropriate.

Stay Connected!

Follow Pfizer IGLC on Twitter!
See more resource links below.



You are receiving this e-mail because you are registered in the Pfizer Grant Management System (GMS) and/or have subscribed to receive communications from Pfizer IGLC. To continue receiving updates, please add IGLC@Pfizer.com to

your address book.

This message was sent to amanda.solis@pfizer.com from:

Pfizer IGLC | IGLC@pfizer.com | Pfizer | 235 East 42nd Street | New York, NY 10017

[Unsubscribe](#)

Email Marketing by

